Biopharmaceutical CMO Roadshow: The Path Forward for CMOs Amidst Pharmaceutical Innovation
Significant Growth Potential: CMO Market in China Maintains Over 10% Growth Rate
The barriers to entry in the custom pharmaceutical R&D and manufacturing industry are relatively high. Although China entered this sector later, it has increasingly become the preferred strategic outsourcing destination for multinational pharmaceutical companies, leveraging its competitive advantages in talent, infrastructure, and cost structure. The CMO market for biopharmaceuticals in China has maintained an annual growth rate of over 10% in recent years.
The global pharmaceutical contract development and manufacturing (CDMO) industry is growing at a faster pace than the overall global pharmaceutical industry, while China’s CDMO sector is expanding even more rapidly than the global average. Consequently, China faces significant growth opportunities in the pharmaceutical CDMO industry.
Policy Tailwinds: Central Government to Invest Over RMB 5 Billion in 2018
On October 8, 2017, the General Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued the “Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices,” promoting in-depth reforms and encouraging innovation through six major areas and 36 specific measures. This signifies that innovation in pharmaceuticals and medical devices has been elevated to a national strategic priority.
On December 28, 2017, the China Food and Drug Administration (CFDA) issued and implemented the “Opinions on Encouraging Drug Innovation through Priority Review and Approval,” which clearly defined the scope, procedures, and work requirements for priority review and approval.
In June 2018, the National Development and Reform Commission (NDRC) released a national subsidy program for biomedical CROs and CMOs, actively promoting the full implementation of the Marketing Authorization Holder (MAH) system.
Not only have policies been frequently issued, but in 2017, the national fiscal investment in the Major New Drug Development Program reached RMB 1.4 billion, clearly demonstrating the state’s strong focus and firm commitment to major new drug innovation. Zeng Yixin, Deputy Director of the National Health Commission, publicly stated that task deployment would be further accelerated and fiscal investment continued to increase, with central government funding for the special new drug program expected to exceed RMB 5 billion in 2018.
Strong national support and the continuous improvement of the market environment have undoubtedly injected new vitality into the innovative drug sector. Currently, dozens of new drugs are approved for clinical trials each year, with countless more projects in the preclinical stage. As R&D efforts advance, a significant number of drugs are expected to gain marketing approval in the future, driving a steady rise in demand for production capacity. CMOs are experiencing business growth in tandem with the increasing order volumes of upstream CROs. Furthermore, under the impetus of the Marketing Authorization Holder (MAH) system, the contract manufacturing outsourcing market has received substantial encouragement, positioning CMOs as key players in the pharmaceutical industry chain.
The Development Path of Pharmaceutical CMOs Amidst the Surge in Medical Innovation
As the CMO industry develops, it also faces challenges. Traditional CMO companies, which rely solely on manufacturing processes and technical support provided by pharmaceutical companies to offer single-mode contract manufacturing services, can no longer fully meet customer demands. Pharmaceutical companies expect CRO/CMO firms to leverage their own production facilities and technological expertise to assume more innovative roles in process development and optimization, thereby helping pharmaceutical companies improve manufacturing processes, enhance synthesis efficiency, and ultimately reduce production costs. Therefore, high-value-added process development and industrial application represent the future development trend of the pharmaceutical manufacturing industry.
Therefore, VCBeat and China Fortune Land Development Co., Ltd. jointly hosted the event themedBiopharmaceutical CMO Meet-and-Greet: “The Development Path of Pharmaceutical CMOs Amid the Surge in Medical Innovation”This event will bring together industry leaders from China’s pharmaceutical and medical device CMO sectors for an intimate salon-style discussion, featuring in-depth exploration, analysis, and exchange of perspectives. Participants will examine the current state of development, challenges, and opportunities within China’s pharmaceutical CMO industry; address key difficulties and pain points encountered during growth; and analyze policy directions and emerging trends. Against the backdrop of vigorous new drug R&D efforts, the discussion will also focus on technological advancements and channel evolution in the pharmaceutical CMO field. Furthermore, the event aims to deepen understanding of complementary resources among enterprises, facilitating the translation of ideological exchanges into tangible collaborations.
Event Theme: The Development Path of Pharmaceutical CMOs Amidst the Surge in Pharmaceutical Innovation
Event Time: November 3, 2018 (Saturday) 14:30-17:00
Venue: Shiliupu Coffee, Hangzhou (No. 4 Baiyun Road, Shangcheng District)
Event Organizers: VCBeat, China Fortune Land Development Co., Ltd.
Event Scale: 30 people
Attendees: Senior executives from pharmaceutical and medical device CMO companies
14:00-14:30 Check-in
14:30-14:40 Address
14:40-15:20 Self-Introduction
15:20-15:35 Opportunities and Challenges in the Pharmaceutical CMO Sector Amid the Rapid Expansion of New Drug Development
15:35-16:10 Free Discussion:
How Can CMOs Capture the Rapidly Growing Market for Innovative Drug Contract Manufacturing?
16:10-16:25 How Can Industrial Parks Help CMO Companies Enhance Technical Value-Added?
16:25-17:00 Free Discussion:
CMO Companies’ Evaluation Criteria for Industrial Parks (Location, Talent Resources)
17:00Banquet
We have invited senior executives from companies in the pharmaceutical and medical device CMO sectors to attend the conference. The companies we plan to invite include:
Yaben Chemical
Shanghai Yaxing Biomedical Technology Co., Ltd.
Shanghai Maofu Chemical Technology Co., Ltd.
LeWei Pharma
Changshan Biochemical Pharmaceutical (Jiangsu) Co., Ltd.
Alpha Pharma
Jiangsu Zhengji Pharmaceutical Co., Ltd.
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Beijing Liuhe Ningyuan Technology Co., Ltd.
Wuhan Lihe Chemical New Materials Co., Ltd.
Qingdao Yunshan Biotechnology Co., Ltd.
Jinan Lemon Biotechnology Co., Ltd.
Nanning Weikai Biotechnology Co., Ltd.
......
Weekend afternoon, by the West Lake—looking forward to meeting you!
Scan the QR Code to Register